Healthcare
Maravai LifeSciences Holdings, Inc.(MRVI)
Live Price
Offline$5.20
-0.38% today
1Y Change
+120.70%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $1.02B
- Revenue Growth
- -28.3%
- EPS Growth
- +13.3%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Maravai LifeSciences Holdings, Inc. (MRVI) is a Healthcare stock with a market cap of $1.02B and listed on NASDAQ. The stock last traded around $5.20 and up 120.7% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -28.3%, EPS growth of +13.3%, a dividend yield of 0.0%. What stands out right now is revenue -28.3%, EPS +13.3%, free cash flow -218.7% with operating margin -3.6% and ROIC -0.9%. Valuation sits in the middle of the pack at price/sales 5.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MRVI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-28.3% vs +7.6% peer median
Operating Margin
Below sector median
-3.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -28.3% and EPS is at +13.3%, with operating margin around -3.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +5.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | -1.7% | -13.9% | +7.6% |
2026 Feb 25, 2026 | +42.9% | +9.2% | +17.2% | -4.6% |
2025 Nov 6, 2025 | -33.3% | -0.7% | +12.5% | +28.0% |
Benchmark Edge
MRVI vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MRVI
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MRVI Max Drawdown
-29.93%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MRVI and SPY.
Company Overview
Maravai LifeSciences Holdings, Inc.
NASDAQ Global Select
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
- Leadership
- Bernd Brust
- IPO Date
- Nov 20, 2020
- Employees
- 570
- Street Address
- 10770 Wateridge Circle
- Mailing
- San Diego, CA, 92121
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 546 0004
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 5.5
- Price/Book
- 2.5
Growth
- Revenue
- -28.3%
- EPS
- +13.3%
- Free Cash Flow
- -218.7%
Profitability
- Gross Margin
- 18.0%
- Operating Margin
- -3.6%
- Net Margin
- -70.4%
- ROE
- -51.1%
- ROIC
- -0.9%
Balance Sheet
- Debt/Equity
- 0.17
- Current Ratio
- 6.60
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.